Copyright © Inderes 2011 - present. All rights reserved.

Genovis

20.35 SEK

-0.49 %

1,634 following

GENO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

-0.49 %
-9.76 %
-11.52 %
-20.35 %
-17.61 %
-18.27 %
-52.06 %
-30.19 %
-25.67 %

Genovis operates in biotechnology. The main focus is on the development of enzymes used in various pharmaceuticals. The company's patented NIMT technology is developed to facilitate the LifeScience industry to conduct preclinical research. The company's products are resold under several brands. Genovis was established in 1999 and is headquartered in Lund.

Read more
Market cap
1.34B SEK
Turnover
660.86K SEK
Revenue
130.36M
EBIT %
35.08 %
P/E
40.7
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12/2
2026

Annual report '25

28/4
2026

Interim report Q1'26

18/5
2026

General meeting '26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.